BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16418875)

  • 21. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
    Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
    Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
    Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
    J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center.
    Khan MA; Masood N; Husain N; Ahmad B; Aziz T; Naeem A
    J Pak Med Assoc; 2012 May; 62(5):430-4. PubMed ID: 22755303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
    Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
    Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Side effect analyses in consideration of renal functions for capecitabine-administered patients].
    Iwai M; Kimura M; Yoshimura T; Yasuda T
    Gan To Kagaku Ryoho; 2012 May; 39(5):783-6. PubMed ID: 22584331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
    Maurer U; Härle M; Jungius KP
    Strahlenther Onkol; 1996 May; 172(5):257-9. PubMed ID: 8633257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G; Haim N
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
    Farina A; Malafronte C; Valsecchi MA; Achilli F
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):722-6. PubMed ID: 19584743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine: an overview of the side effects and their management.
    Saif MW; Katirtzoglou NA; Syrigos KN
    Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
    Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
    Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
    Chua D; Wei WI; Sham JS; Au GK
    Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine induced vasospastic angina.
    Coughlin S; Das S; Lee J; Cooper J
    Int J Cardiol; 2008 Oct; 130(1):e34-6. PubMed ID: 17897740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
    Karakulak UN; Aladağ E; Maharjan N; Övünç K
    Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Myocardial ischaemia as a result of treatment with capecitabine].
    van Halteren HK; Liem AH; Planting AS
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1469-73. PubMed ID: 17633978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.